Rituxan, Herceptin, Gleevec pricing (correction)
Executive Summary
The wholesale acquisition cost of Genetech's Rituxan is $13,041 for a one-month course as monotherapy for relapsed/refractory, low grade or follicular, CD20+, B-cell non-Hodgkin's lymphoma and $19,561 for diffuse large CD20+ B-cell NHL (4.2 month average course of treatment); the firm's Herceptin has a WAC of $22,521 for metastatic breast cancer (7.2 month average course at $3,042 per month). According to data from Price Alert, the average wholesale price for Novartis' Gleevec ranges from approximately $3,348.27 to $5,022.36 per month for adults. "The Pink Sheet" reported a discussion of the pricing of the targeted oncologics that was based on inaccurate figures (1"The Pink Sheet" June 26, 2006, p. 22)...